No Data
No Data
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $19 price target.
Express News | Oncternal to Provide Onct-534 Study Update Q3 2024
Express News | Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $28.00 to $19.00.
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $28.00 to $19.00.